The endovascular device market for acute ischemic stroke (AIS) is facing several challenges that could slow market growth, including negative clinical trial results, threats to reimbursement, increasing regulatory requirements, and a challenging funding environment. (See Also see "Stroke Devices: Hope Amid Headwinds" - Medtech Insight, 27 September, 2013..) Despite these headwinds, market leader Medtronic Minimally Invasive Therapies sees opportunity ahead and believes AIS treatments will play a significant role in the future growth of its neurovascular division. According to Brett Wall, president of Covidien’s neurovascular division, who spoke recently with Medtech Insight, there are a number of clinical trials ongoing with Covidien’s Solitaire line of neurothrombectomy devices, and the firm has a strong commitment to the neurointerventional space.
In January 2013 Covidien began enrolling patients in the Solitaire FR as Primary Treatment for Acute Ischemic Stroke (SWIFT PRIME) study, a randomized, controlled, multicenter prospective trial that will compare...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?